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THREE-DIMENSIONAL CULTURED GLIOMA CELL LINES
The invention relates to three-dimensional glioma spheroids produced in vitro.
Three-dimensional glioma spheroids have been produced in vitro with size and
histological differentiation previous unattained. The spheroids where grown in
liquid media suspension in a JSC Rotating Wall Bioreactor without using support
matrices such as microcarrier beads. Spheroid volumes of greater than 3.5 mm3
and diameters of 2.5 mm have been achieved with a viable external layer or rim
of proliferating cells, a transitional layer beneath the external layer with
histological differentiation and a degenerative central region with a hypoxic
necrotic core. Cell debris was evident in the degenerative central region. The
necrotic centers of some of the spheroids had hyaline droplets. Granular bodies
were detected predominantly in the necrotic center.
The external layer was often more than 15 cell layers thick, densely packed, and
measured from 100 to 250 microns thick. The transitional region has pleomorphic
cells with pleomorphic nuclei. The transitional cells are less densely packed
than the external layer and are circumferentially oriented whereas the external
layer has rounded cells with round nuclei, almost radially arranged.
The spheroids exhibited active cellular metabolism. Certain spheroids had
extensive pleomorphism with giant cell formation and polymorphism and mitosis in
the cellular nuclei. The spheroids expressed detectable glial fibrillary acid
protein. Fibronectine and vimentin were expressed.
The artificially generated three-dimensional avacular spheroids of the present
invention are in vitro produced models of prevascular tumors useful for human
tumor ontogeny and evaluation of potential anti-tumor therapies. The histo-
logical and metabolic resemblance to in vivo tumors is superior to earlier
attempts to reproduce spheroid growth in vitro.
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THREE-DIMENSIONAL CULTURED GLIOMA CELL LINES
ORIGIN OF THE INVENTION
The invention described herein was made by employees
of the United States Government and may be manufactured and
used by or for the Government of the United States of
America for governmental purposes without the payment of
5 any royalties thereon or therefor.
BACKGROUND OF THE INVENTION
Cell and tissue culture is essential to neurobiolog-
ical research concerning transformation of neural cells and
tumor cell invasiveness. Laerum, O. D. , et al., "Monolayer
10 and Three-Dimensional Culture of Rat and Human Central
Nervous System: Normal and Malignant Cells and Their
Interactions", 2 Methods in Neurosciences 210-236 (1990).
For example, cultured malignant glioma cells are frequently
selected for general neurobiological studies. However,
15 because cell culture cannot replace the complex conditions
existing in the brain, it is important that the functions
investigated in vitro mimic to the extent possible in vivo
properties of the same cells.
Malignant tumor growth takes place in a three-dimen-
20 sional fashion. Solid tumor tissue forms and then spreads
as single cells into the surrounding normal tissue matrix.
Generally, in vivo grown tumors consist of a complex of
tumor cells, , an extracellular matrix and vessels, and a
variable number of inflammatory cells. (Laerum, 0. D., et
25 al.)
In the in vivo state, abnormal vascularization of
malignant tumors is associated with the development of
microregions of heterogeneous cells and microenvironments.
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Sutherland, R. M. , "Cell and Environment Interactions in
Tumor Microregions: The Multicell Spheroid Model", 240
Science 177-184 (April 8, 1988). The cellular heterogene-
ity of tumors may explain the behavior of growing tumor
5 cell populations with different metastatic propensities and
drug resistances. The cellular heterogeneity of tumors is
also reflected by variations in the expression of cellular
antigens, which can complicate the use of antibodies
conjugated with cytotoxic agents and by variations in
10 specific chromosomal abnormalities. (Sutherland, R. M.
(1988)) As an example, gliomas are known to be
heterogenous tumors, showing a wide range of phenotypic
properties within the same primary tumor or continuous cell
line. (Laerum, 0. D., et al. (1990))
15 In vivo tumor growth is characterized by a phase of
exponential cell proliferation followed by a phase of
declining growth rate associated with an increase in
nonproliferating (quiescent) cells and necrotic cells.
(Laerum, 0. D., et al.; Carlsson, J., et al., "The Fine
20 Structure of Three-Dimensional Colonies of Human Glioma
Cells in Agarose Culture", 85 Acta Path. Microbiol. Scand.,
Sect. A 183-192 (1977); Sutherland, R. M., et al., "Growth
and Cellular Characteristics of Multicell Spheroids", 95
Recent Results in Cancer Research 24-49 (1984)) Jn vivo
25 tumors frequently begin as avascular spheroids having an
external layer of densely packed viable proliferating
cells, a transitional layer of less densely packed viable
cells and a central necrotic region of hypoxic, quiescent
cells. (Sutherland, R.M. (1988); Carlsson, J. et.al.,
30 (1984)) Avascular in vivo tumor spheroids having a
diameter of approximately 2mm are frequently reported.
(Sutherland, R.M.,- (1988)) The external layer of various
in vivo tumors have been found to be up to 200 /xm in
thickness. (Sutherland, R.M., (1988))
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Proliferating tumor cells are usually located within
a few cell layers of functional blood vessels. Quiescent
and necrotic cells are located at progressively greater
radial distances from the vessels. Carlsson, J., et al.,
5 "Liquid-Overlay Culture of Cellular Spheroids'', 95 .Recent
Results in Cancer Research 1-23 (1984) . The radii measured
between the vessels and necrotic areas in a variety of
human tumors range from approximately 50 to 250 /*m.
(Sutherland, R. M. (1988))
10 Angiogenesis generally occurs in tumors that have
reached l to 2 mm in diameter. (Sutherland, R. M. (1988))
Vascularization facilitates the delivery of nutrients,
substrates and oxygen to individual cells, the removal of
cellular waste products, and enhances the distribution of
15 therapeutic agents throughout the tumor growth. During
prevascular tumor growth, the effectiveness of therapeutic
agents may be limited as a result of poor distribution of
the agent to mitotic cells. There seems to be a signifi-
cant influence of the tissue environment on the efficiency
20 of the vascular supply that develops. Data suggests that
the intratumor distributions of important substrates such
as glucose or other nutrients, as well as growth factors or
hormones may also be deficient and heterogeneous. (Laerum,
O. D., et al.; Sutherland, R. M. (1988))
25 In vivo tumors vary greatly genetically. (Sutherland,
R.M. et al., 1984)) Generally, DNA analysis of in vivo
tumors of similar cell types will demonstrate
quantitatively similar degrees of abnormality. Many,
though not all, in vivo tumors have been shown to be aneu-
30 ploid in nature . ,
The three-dimensional in vitro spheroid tumor model is
intermediate in complexity between standard two-dimensional
monolayer cultures in vitro and tumors in vivo. Spheroids
are grown in liquid media allowing three-dimensional growth
35 as compared to two-dimensional monolayer cultures grown on
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a surface. In vitro cultured spheroids demonstrate overall
growth characteristics similar to those of tumors in vivo,
and reflect the growth rates of the same cell types as
tumors in vivo more closely than do monolayer cultures.
5 (Sutherland, R. M. (1988); Sutherland, R. M, et al. (1984))
In vitro cultured spheroids generally consist of three cell
layers that are somewhat similar morphologically and
histologically to the cell layers found in in vivo tumor
spheroids.
10 Generally, most of the proliferating cells found in in
vitro produced spheroids are located in the outer three to
five cell layers. (Sutherland, R. M. (1988)) The
quiescent cells are located more centrally and may include
a significant proportion of cells that are reproductively
15 viable when removed from these environments. (Sutherland,
R. M. (1988)) The distance from the periphery at which
necrosis occurs varies from 50 to 300 /im. The spheroid
colonies are nearly round in shape. The shape and
characteristics of the individual cells in the outer and
20 transitional layer vary. (Carlsson, J. et al., (1984))
Although in vitro spheroids are more sensitive to
alterations in culture environment than are monolayer or
single-cell suspension cultures, spheroids provide a model
which at different stages of growth is readily manipulated
25 and controlled experimentally. In vitro spheroids
facilitate studies of contributions of individual envi-
ronmental factors, or concomitant changes in these, on
cellular phenotypic expression. It is probable that
cellular changes which can be demonstrated to occur during
30 in vitro spheroid growth also occur in vivo. (Sutherland,
R. M. (1988))
An important influence of in vitro spheroid cell
heterogeneity, as to the development of quiescent cells, is
the influence of nutritional factors, oxygen tension (p02),
35 and central necrosis on cellular phenotypic properties.
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For some in vitro spheroid types, the thickness of the
viable rim of cells surrounding the necrotic center
correlates with the theoretical oxygen and glucose pene-
tration distance. However, the availability of other
5 important nutrients, such as glucose, play an important
direct or indirect role in controlling the development of
central necrosis. (Sutherland, R. M., et al. (1984))
Studies have shown that the maximum spheroid size (volume
and cell number) at growth saturation is positively
10 correlated with the oxygen and glucose concentrations of
the medium. Spheroid growth characteristics and cellular
properties are significantly influenced by spheroid cellu-
lar metabolism and the microenvironmental conditions during
the culture period. (Sutherland, R. M., et al. (1984))
15 Culture conditions influencing spheroid growth include
constituents of the culture medium, frequency of
replenishment of the medium, the oxygen and glucose con-
centrations and the convection properties of the culture
medium. (Sutherland, R. M., et al. (1984))
20 Techniques have been developed for producing in vitro
three-dimensional spheroids to mimic in vivo tumor cell
growth; however, limiting aspects of such techniques are
frequently reported. Generally, as growth of in vitro
produced spheroids progresses, the number of cells that are
25 proliferating decreases, and the proportion of non-
proliferating (quiescent) cells increases. (Sutherland, R.
M., et al. (1984); Sutherland, R. M. (1988)) When cells
become deprived of oxygen, glucose, and other substrates,
and when toxic metabolic waste products accumulate, there
30 are steep gradients in these metabolites, and cell death
and necrosis will usually occur in the center of the
spheroids. The distance from the periphery of the spheroid
at which necrosis occurs may vary from 50 to 300 pm,
depending on the cell types, the concentrations of
35 substrates in the growth media, and the overall diameter of
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the spheroid. (Sutherland, R. M. (1988); Carlsson, J., et
al. (1977)) For most types of human tumor cells grown
under optimal nutrient and oxygen conditions in vitro, the
thickness of the viable rims of cells surrounding the
5 necrotic centers of spheroids ranges from 100 to 220 /m.
(Sutherland, R. M. (1988))
A principal method for producing spheroids in vitro,
though not suitable for all cell types, is a stirred
suspension culture in Spinner flasks. Some cell types have
10 been used to produce spheroids of up to 1000 /im or larger
using this technique; however, most spheroids produced will
have a considerably smaller diameter (< 400 /urn) .
Additionally, cell shedding from spheroid surfaces is seen
with spheroids grown in Spinner flasks. Cell shedding from
15 high shear forces likely attributes to the low volume and
frequently small diameter cell colonies produced by Spinner
flask culture. (Sutherland, R.M., et al. (1984))
Three-dimensional growth of colonies or aggregates of
tumor cells in semisolid medium agar, agarose or
20 methylcellulose has also been described. The three-
dimensional, proliferative growth in vitro starting from
single cells, demonstrated in suspension culture or by
tumor cells in a semisolid medium is restricted by
insufficient diffusion of oxygen and nutrients and by the
25 accumulation of catabolic products. (Sutherland, R. M., et
al. (1984))
Human malignant glioma cells grown in agarose culture
were found to be morphologically tumor-like, but did not
exhibit the massive degeneration in the centers of the
30 spheroid colonies that is seen with other culture methods.
(Carlsson, J., et al. (1977)) Central necrosis was only
seen in older colonies that had reached a plateau phase of
growth. The spheroids grown in the agarose culture only
reached diameters of approximately 600 /im. (Carlsson, J.,
35 et al. (1977))
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Spheroids of glioma cells grown in liquid-overlay
culture have been grown to maximum diameters ranging from
about 0.9 to 1.2 mm. (Carlsson, J. , et al. (1984)).
However, spheroids grown using this method will more
5 frequently have diameters of approximately 250-600 urn.
Liquid overlay cultures have been shown to produce
spheroids having less than optimal peripheral nutrient and
gas exchange. Necrotic zones appeared when the glioma
spheroids had reached diameters of about 300 /m.
10 Thereafter, the size of the necrotic regions continuously
increased. The thickness of the viable cell layers reached
a maximum at about the same time that necrosis first
appeared.
Other methods for producing in vitro three-dimensional
15 spheroids have been reported. Systems utilizing a
preserved tissue matrix (spheroid grown in a semisolid agar
where no shaking is required) observe an initial size
reduction and high rate of cell death. (Laerum, O. D., et
al.) Modified organ culture methods involving an overlay
20 suspension containing tumor pieces have also been
developed. (Laerum, 0. D., et al.) Spheroids produced by
this method maintained a close similarity to the histology
of the original tumor for the entire culture period,
including similarity in morphology of the tumor cells and
25 matrix, as well as preservation of small vessels. A
limitation of the modified organ culture method is the
large areas of necrosis that are characteristic of
glioblastomas in vivo. In these spheroids, necrotic areas
may occasionally be seen, as well as small areas of
30 degenerated tumor tissue. Cells were also shed from spher-
oids produced by this method. As a result, cell prolifera-
tion did not lead to spheroid growth.
The usefulness of spheroids as research vehicles is
dependent upon the three-dimensional colonies closely
35 mimicking in vivo tumors morphologically, histologically,
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and functionally. The presently used methods for producing
spheroids have been shown to produce spheroids having
particular limitations. Tumor aggregates produced using
Spinner flask cultures result in low volume colonies having
5 diameters of less than 400 /urn. Furthermore, shedding of
the periphery cells occurs, thus preventing increased
diameters of the spheroids produced by this method. Spher-
oids produced in liquid overlay cultures are also generally
small (250-600 /urn) in diameter and have reduced peripheral
10 nutrient and gas exchange. Similarly, other presently uti-
lized methods for producing spheroids discussed above fail
to imitate in vivo tumor cells.
Histological criteria of malignancy in human glioma
tumors in vivo include extensive pleomorphism with giant
15 cell formation as well as polymorphism and mitosis within
cellular nuclei, a hypoxic necrotic core, down-regulation
of glial fibrillary acid protein (GFAP) expression, and in-
creased expression of fibronectin. Observation of similar
criteria within in vitro glioma spheroids may qualify the
20 present invention as an in vitro model for both human tumor
cell biology and the evaluation of innovative antitumor
therapies.
Spheroids provide a unique system in which to simulate
the conditions of clinical therapy in vitro. The three-
25 dimensional arrangement of cells in in vitro spheroids can
permit various combinations of physical, chemical, and nu-
tritional stress factors to be tested under conditions that
resemble those of poorly vascularized cords or nodules in
solid tumors. The penetration of cytotoxic substances may
30 be limited by poorly vascularized tumor tissue. It is
essential that the spheroids cultured from tumor cell lines
be of similar ^ size and dimension to in vivo spheroids in
order to accurately determine the potential effectiveness
of particular methods of therapies. In vitro screening of
35 chemotherapeutic agents may utilize multicellular tumor
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spheroids of diverse origins for such purposes. For
example, an in vitro grown and maintained glioroa cell line
which closely imitates the characteristics of in vivo grown
gliomas would enable "customizing" cancer therapies to
5 particular types of gliomas, as well as to specific malig-
nant gliomas from individual patients.
SUMMARY OF THE INVENTION
Three dimensional glioma spheroids have been produced
in vitro with size and histological differentiation
10 previously unattained. The spheroids were grown in liquid
media suspension without using support matrices such as
micro-carrier beads. Spheroid volumes of greater than
3. 5mm3 and diameters of 2. 5mm have been achieved with a
viable external layer or rim of proliferating cells, a
15 transitional layer beneath the external layer with
histological differentiation and a degenerative central
region with a hypoxic necrotic core. Cell debris was
evident in the degenerative central region. The necrotic
centers of some of the spheroids had hyaline droplets.
20 Granular bodies were detected predominantly in the necrotic
center.
The external layer was often more than 15 cell layers
thick, densely packed, and measured from about 100 to 250ji
thick. The transitional region has pleomorphic cells with
25 pleomorphic nuclei. . The transitional cells are less
densely packed than the external layer and are
circumferentially oriented whereas the external layer has
rounded cells with round nuclei, almost radially arranged.
The spheroids exhibited active cellular metabolism.
30 Certain spheroids had extensive pleomorphism with giant
cell formation and polymorphism and mitosis in the cellular
nuclei. The spheroids expressed detectable glial
fibrillary acid protein (GFAP). Fibronectin and vimentin
were expressed.
 ; ;
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The artificially generated three dimensional avascular
spheroids of the present invention are in vitro produced
models of prevascular tumors useful for human tumor
ontogeny and evaluation of potential antitumor therapies.
5 The histological and metabolic resemblance to in vivo
tumors is superior to earlier attempts to reproduce
spheroid growth in vitro.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a photograph of an artificial three-
10 dimensional spheroid with a diameter of 2.1mm cultured from
a malignant human glioma cell line.
Figure 2 is a 10 p. cross cryosection (magnification =
160X) of an artificial three-dimensional glioma spheroid of
astrocytoma cell line of Example 1.
15 Figure 3 is a 2 /i paraffin cross section
(magnification = SOX) of an artificial three-dimensional
glioma spheroid of astrocytoma cell line of Example 2.
Figure 4 is an increased magnification (magnification
= 160X) view of the artificial three-dimensional glioma
20 spheroid of Example 2.
Figure 5, is a 320X magnification of cells of the
artificial three-dimensional glioma spheroid of Example 2.
DETAILED DESCRIPTION OF THE INVENTION
The artificial three-dimensional glioma spheroids were
25 generated from malignant human glioma cell lines previously
grown in anchorage-dependent monolayer culture conditions.
Single cell suspensions were prepared and introduced into
a bioreactor with liquid media in a low shear environment.
The single cells aggregated, compacted and grew to form
30 spheroids up to 2.5mm in diameter. The cellular growth
along the periphery of the cell aggregates produced a
viable rim.
10
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A photograph of one of the artificial three-dimension-
al spheroids is shown in Fig. 1. The spheroid was generat-
ed from the anchorage-dependent astrocytoma cell line CS
discussed in Example 2. The spheroid shown has a diameter
5 of approximately 2.1 mm after 13 days in culture. The
smooth, round characteristic of the spheroid is evident.
The spheroid shown is an avascular tumor model for evaluat-
ing tumor therapy as well as studying tumor growth and
factors affecting growth. Poorly vascularized tumors have
10 been noted as resistant to conventional therapies.
The spheroids of the invention prepared from different
cell lines have active cellular metabolism and develop with
significant histological differentiation resembling in vivo
spheroids. The rim or outer layer of cells are dense and
15 dividing. The spheroids have a degenerative central region
with a necrotic core. The spheroids have extensive and
progressive pleomorphism. These histological criteria are
exemplary of glioblastoma. The spheroids are exemplary of
the three dimensional tissue growth for various glioma cell
20 lines and is not intended to limit the invention to a par-
ticular embodiment.
Human glioma samples were grown and trypsinized to
separate the individual cells. A high density inoculum of
at least half a million cells per milliliter was preferred.
25 The spheroids were cultured under low shear conditions in
liquid media that.allowed for catabolic waste exchange and
nutrient supply. Specifically, the clinostatic bioreactor
used was a High Aspect Ratio Vessel as described in the
published patent, application 'by the National Aeronautics
30 and Space Administration in the Scientific and Technical
Aerospace Reports Volume 29/Number 9, May 8, 1991, ACC NOS.
N91-17531, U.S. Serial No. 625,345, entitled "A Culture
Vessel With Large Perfusion Area To Volume Ratio," invented
by David A. Wolf, Clarence F. Sams and Ray P. Schwarz and
35 filed on December 11, 1990, which application is
11
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incorporated by reference in its entirety in this
specification. Other bioreactors that provide for
suspension of the cells with homogeneous nutrient
distribution and gas exchange under low shear conditions
5 can be used to generate the artificial spheroids.
After several hours, cells start to aggregate. After
a day or two of culture, aggregates form and afterwards
compact. Initially, the aggregate is roughly spherical
with a ragged surface. The spheroid then compacts
10 increasing in cell density, and the cells in the outer
layer show increased mitotic activity. The spheroids
develop in a uniform manner. After at least five weeks of
culture in a low shear bioreactor, the peripheral layer
remained viable and active.
15 Example 1
Astrocytoma cell line designated HBR09 available from
the Huntington Medical Research Institute is an example of
a suspension of a normally anchorage-dependent cell line
used to generate three-dimensional spheroids of the present
20 invention. The cells were independently passaged and
cultured from a confluent monolayer grown prior to
suspension in the bioreactor. The monolayer cultures were
trypsinized in T-flasks for 10 minutes at 37°C with 0.25%
Trypsin in ImM EDTA and media composed of Dulbecco's
25 Modified Eagle's/Ham's-F-12 (Gibco BRL Life Technologies,
Inc.) (1:1) + 5% fetal bovine serum (Hyclone Laboratories,
Inc.) with 100 units/ml of penicillin and 100 ng/ml of
streptomycin. The trypsinized cells were centrifuged for
5 minutes at 1000 rpm (20°C) and resuspended in fresh media
30 at 37°C.
A suspension of 1.25 x 107 cells harvested from log-
phase anchorage-dependent cells was introduced into the
bioreactor in 50 ml of media. A minimum glucose
concentration of 250 mg/dL and a pH of 7.2-7.3 were
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maintained during the culture period. A 20 ml daily
replacement of fresh conditioned culture medium was
prewarmed to 37°C and added to the bioreactor. The vessel
was rotated to maintain suspension of the spheroids and
5 minimize collisions with the cell wall. When the cells
were cultured for more than 21 days in the low shear
bioreactor, the cells aggregate and divide to form a
spheroid of relatively uniform size with volumes greater
than 3.5 mm3.
10 The spheroids were removed from the bioreactor and
prepared for histological examination. For paraffin
sectioning the spheroids were fixed with 2%
paraformaldehyde, washed three times and dehydrated with
graded ethanol series and infused with xylene. After
15 paraffin embedding and sectioning, the spheroid sections
were deparaffinized and stained with (Harris)
hematoxylin/eosin, toluidine blue or oil red O. For
plastic sectioning, samples were fixed and dehydrated using
the same method and embedded in water-soluble JB-4 (Poly-
20 sciences, Inc.)- Samples were sectioned (2/x) on a MT-2
Porter-Blum ultramicrotome and stained with hematoxylin/eo-
sin or toluidine blue. For cryosectioning, the spheroids
were fixed, washed and infused with 0.5 M sucrose for 2
hours, washed twice with cold PBS, embedded in Histo-Prep
25 - (Fisher Scientific Co.) and rapidly frozen in liquid nitro-
gen-cooled isopentane. The samples were sectioned on a
Reichart Histostat microtome, air dried and stained with
hematoxylin/eosin or toluidine blue and examined.
Viable cells were more numerous and more densely
30 packed in the spheroids' outer rim, which was 100-250/Li
thick, than in the other two layers. Continued cellular
growth along the periphery of the spheroids resulted in a
proliferating, external, viable rim of cells..
The spheroids with volumes greater than 3.5 mm3 were
35 characterized morphologically from cryosections as
13
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progressively pleomorphic with the appearance of giant
multinucleated cells. The spheroids of Example 1 with
volumes greater than 4.2mm3 had extensive pleomorphism with
giant cell formation. The central region of the spheroids
5 were degenerative and characterized by small, round dark
staining nuclei. The spheroids had necrotic cores
containing cellular debris, numerous hyaline droplets and
granular bodies.
Figure 2 is an approximately 10 n thick cryosection of
10 a spheroid of Example 1. The spheroid shown is
approximately 2.1mm in diameter, with a volume in excess of
4.2 mm3. The three distinct cell layers are seen: an
external layer of viable, proliferating cells indicated by
bracket 10; a transitional region indicated at bracket 12;
15 and a degenerative central region indicated at bracket 14.
The extensive cellular and nuclei pleomorphism is evident.
Giant, multinucleated cells are shown as indicated at
numeral 18. Spindle cells are also present as indicated at
numeral 16. The viable outer layers of cells 10 are
20 characterized by tandem swirling patterns of elongated
cells with lighter staining ovoid nuclei and rough plasma-
lemma. The viable cells are more numerous and more densely
packed in the external layer 10 (» 100-250 urn thick) than
in the transitional region 12 or the degenerative central
25 region 14.
The artificial three-dimensional spheroids of this
example were similar to astrocytic neurosurgical specimens.
Both the artificial spheroids and cystic astrocytomas and
oligodendrogliomas have many hyaline droplets and granular
30 bodies.
Example 2
Cell suspensions have been prepared from an anchorage-
dependent astrocytoma cell line CS from Huntington Medical
Research Institute, Pasadena, California. The cells were
14
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grown in monolayers and trypsinized as described above.
The cells were introduced into the bioreactor and cultured
as described in the Example 1. The cells readily formed
three-dimensional tumor spheroids without any type of sup-
5 port matrix. The cells of Example 2 divided more rapidly
than Example 1, indicating more advanced malignancy
of the cell line. After 21 days of culture in the
bioreactor, glioma spheroids had volumes greater than
3. 5mm3.
10 The spheroids were examined for morphological and
histological characteristics employing the sectioning and
staining techniques previously described in Example 1.
Figure 3 is a 2 /i cross section of the glioma cell line of
Example 2. Figure 3 shows the spheroidal shape with a
15 relatively smooth surface as a result of the dense aggrega-
tion of cells. In the cross sectioning, part of the
external layer is not shown. The external layer of cells
on the periphery of the spheroid is indicated at 20. The
density of the external layer is evident.
20 Beneath the external layer 20 is a less dense
transitional layer 22 which was circumferentially oriented.
The transitional layer had pleomorphic characteristics
including rounded, spindle and giant cells. The nuclei
were pleomorphic. Included in the transitional layer 22
25 were some mitoses as well as some pyknotic cells with small
dark staining nuclei.
The central region 24 consisted of a necrotic zone
containing cell debris and pyknosis. A decrease in the
number and size of intra-cellular lipophilic vacuoles was
30 evident in the cells distal to the necrotic core. The
histology was indicative of a high-grade astrocytoma. The
three histological layers of Example 2 generally correlates
to Example 1.
Figure 4 is an increased magnification of a spheroid
35 of Example 2. The paraffin section shows the external
15
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layer indicated at bracket 30 of viable relatively
monomorphic proliferating cells up to 15-17 layers deep.
The external layer 30 is radially oriented predominantly
monomorphic cells.
5 The pleomorphic nature of the transitional layer
indicated at bracket 32 is more evident in Figure 4.
Spindle cells 36, 37, giant multinucleated cells 38, 39,
and round cells 40, 41 are found in the transitional layer.
The change in cell orientation from radially in the
10 external layer 30 to circumferentially in the transitional
layer 32 is seen in Figure 4. The central region is
indicated by brackets 34 in Figure 4. The densely stained
nuclei are evident of the hypoxic necrotic core.
Figure 5, which is the spheroid of Example 2 shown
15 under greater magnification, shows a giant, multi-nucleated
cell 52 undergoing mitotic division. Spindle cells 50 and
51 can also be seen.
DNA analysis involving cell cycle and ploidy
determination of Example 2 (CS) in vivo collected and in
20 vitro cultured glioma cells was performed using flow
cytometry methods. Handbook of Flow Cytometry Methods, J.
P. Robinson, Ed., Purdue University (1990). DNA synthesis
of in vivo glioma cells was compared to DNA synthesis of in
vitro cultured glioma cells obtained from the same biopsy.
25 The data was derived from cells in the G1 phase of the cell
cycle.
Because of great variations genetically between types
of tumors grown in vivo, DNA Index (DI) values serve as an
internal comparison of the quantitatively similar degree of
30 abnormality found between the biopsy tumor cells and the
spheroids cultured in vitro from the same cells.
The DI values reported in Table I for brain biopsy
glioma cells are similar to those reported in Table II for
in vitro cultured spheroids. The similar DI values of 1.21
35 and 1.35 for brain biopsy versus 1.77 and 1.30 for Example
16
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2 spheroids demonstrate that the degree of hyperdiploidy is
quantitatively similar between the in vivo tumor cells and
the in vitro produced spheroids.
TABLE I
DNA IMAGE CYTOPHOTOMETRY OF BRAIN BIOPSY GLIOMA CELLS
SPECIMEN DNA MASS
CS-BB-1:
CS-BB-1:
mass pg
8.7
9.7
area pm2
38.1
25.3
DI
1.21
1.3510
CS-BB-1 = BRAIN BIOPSY = ANEUPLOID
CS-BB-1 = BRAIN BIOPSY = ANEUPLOID
The DI values reported in Table II for glioma cells
15 cultured in monolayers indicate a considerably greater
degree of hyperdiploidy than that seen with either the
biopsy cells or the spheroid cells. The DI values show
that the spheroids cultured from the biopsy cells closely
mimic the cell kinetics of the in vivo cell line from which
20 it was derived.
DNA IMAGE CYTOPHOTOMETRY OF IN VITRO CULTURED GLIOMA CELLS
SPECIMEN DNA MASS
25
CS-ML-7
CS-ML-14
CS-SP-7
CS-SP-14
mass pg
17.8
17.9
12.7
9.3
area /jm2
144.6
166.5
47.9
35.0
DI
2.48
2.49
1.77
1.30
30
CS-ML = MONOLAYERS = TETRAPLOID
CS-SP = SPHEROIDS = ANEUPLOID
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Immunohistologieal testing was performed on spheroids
generated by both Examples 1 and 2. Tissue sections were
deparaffinized with xylene for 10 minutes, permeabilized
with methanol at -20°C for 30 minutes and rehydrated by a
5 reverse ethanol gradient. Mouse monoclonal antibodies
anti-GFAP [clone G-A-5; Sigma Chemical Co.] and anti-
vimentin [clone Vim 3B4; Boehringer-Mannheim] were used at
a concentration of 10 /xg antibody/ml in a 5% skim milk
medium in PBS for 4 hours at room temperature. Rhodamine-
10 conjugated rabbit anti-mouse IgG (H & L) [ICN Biomedicals,
Inc.] was used as a secondary antibody at a 1:1000 dilution
in 5% skim milk in PBS for 45 minutes at room temperature.
The expression of glial fibrillary acidic protein (GFAP)
was present. Fibronectin expression was elevated as
15 compared to expression in the monolayer cultures.
The embodiment of Example 1 and Example 2 of the
present invention is an artificial three-dimensional
spheroid of human glioma cells which closely mimics the
morphological and histological characteristics of
20 prevascular in vivo glioma tumors. The embodiments
described in Example 1 and Example 2 are exemplary of the
present invention and the invention is not limited by
Example 1 and 2. The invention relates to all glioma
tumors and cell lines. There may be modifications made to
25 the described invention that are apparent to those skilled
in the art.
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ABSTRACT
Artificial three-dimensional glioma spheroids with
histological differentiation were generated from malignant
human glioma cell lines previously grown in anchorage
dependent monolayer culture conditions. The spheroids have
5 an external layer of dense, generally radially arranged,
viable, proliferating cells. The central region has a
hypoxic necrotic core with a transitional region between
the external layer and the necrotic central region. The
transitional region has pleomorphic cells containing
10 pleomorphic nuclei, with the cells being circumferentially
oriented. The central region also has pleomorphic cells
containing pleomorphic nuclei. The spheroids generally
have a diameter of at least 1.2 millimeters.
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